Global Biomarker Testing Market - 2024-2031
Global Biomarker Testing market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
Biomarker testing is the use of a laboratory test to measure biomarkers found in blood, other body fluids, or tissue. Biomarker testing can be somatic or germline. Biomarker testing is also done to select treatments for people who are diagnosed with certain types of cancer.
Biomarker testing helps patient receive the specific treatment best suited to combat their specific disease. A growing majority of new trial results and FDA approvals in cancer, for instance, are for targeted therapies with associated biomarkers.
Market Dynamics: Drivers & Restraints
Rising research and development of new biomarker tests
The increasing research and development of biomarker testing methods is expected to drive market growth. The development of new biomarker tests helps in identifying a wider range of diseases and conditions earlier and more accurately. This allows for better disease management, improved patient outcomes, and potentially earlier interventions to prevent disease progression.
Major players are introducing novel testing methods for the identification and treatment of various diseases which is expected to drive the market growth. For instance, in March 2024, LabCorp launched its biomarker test to identify the presence or absence of phosphorylated tau 217 (pTau217), a pivotal blood biomarker designed to aid in the diagnosis of Alzheimer's disease and the subsequent monitoring of patients undergoing treatment with new Alzheimer's disease therapies.
Additionally, in October 2023, Lucent Diagnostics expanded its LucentAD product line with the addition of a high-accuracy p-Tau 217 blood test for Alzheimer’s disease – LucentAD p-Tau 217. This test marks a major advance in the performance of scalable immunoassay-based blood biomarker tests intended for assessing amyloid pathology in individuals with memory complaints. Thus, the above factors are expected to drive the market growth.
High costs of test development
The market is expected to be hampered by the development costs of the tests. Developing and validating new biomarker tests is expensive which requires a significant investment in research and clinical trials. This can limit the number of new biomarkers available for testing.
Segment Analysis
The global biomarker testing market is segmented based on test type, biomarker type, application, end-user and region.
Tumor Testing segment is expected to dominate the market growth
It is anticipated that the biomarker testing industry will be dominated by the tumor testing segment. The prevalence of cancer is rising making it one of the world's leading causes of death. The need for diagnostic instruments to identify, categorize, and track cancer is fueled by the rising number of cancer cases. Tumour testing is becoming more common as people are becoming more aware of cancer diagnosis and treatment.
For instance, according to the report published by the National Library of Medicine in 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States.
Additionally, the World Health Organization in 2022, has estimated that around 53.5 million individuals have been diagnosed with cancer and are living for more than 5 years. Thus, the above factors are expected to hold the segment in the dominant position in the market share.
Geographical Analysis
North America is expected to hold a significant position in biomarker testing market share
North America boasts a well-established network of research institutions, universities, and pharmaceutical companies heavily invested in biomarker discovery and development. This strong foundation in R&D fuels innovation and leads to the creation of new biomarker tests at a rapid pace. The increasing launches of tests, strategies by the major players in the region and the increasing funds for the research activities by the government are expected to hold the region in the dominant position.
For instance, in August 2023, Quest Diagnostics entered into a partnership with Envision Sciences for the commercial launch of a novel prostate cancer biomarker test for identification of severe and aggressive forms of the disease.
Additionally, in July 2023, Quanterix Corporation launched LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer’s disease (AD). Thus, the above factors are expected to drive the market growth in the region and are expected to hold the dominant position in the market share.
COVID-19 Impact Analysis
COVID-19 has a positive impact on the market growth. The market was stimulated by the increased need for blood gas monitoring equipment in clinics and hospitals. Point-of-care blood gas monitors have grown in value because of their portability and speedy results delivery, which help COVID-19 patients make timely treatment decisions. However, lockdowns and travel restrictions caused delays in the production and delivery of medical supplies, notably blood gas monitors, which resulted in a shortage of equipment in some areas. Thus, the pandemic has a moderate impact on the market.
Market Segmentation
By Test Type
• Tumor Testing
• Genomic Testing
• Molecular Testing
• Somatic Testing
• Next Generation Sequencing
By Biomarker Type
• Diagnostic Biomarkers
• Prognostic Biomarkers
• Predictive Biomarkers
By Application
• Drug Discovery and Development
• Disease Diagnostics
• Disease Risk Assessment
• Personalized Medicine
• Others
By End-User
• Hospitals
• Clinical Laboratoratories
• Academic and Research Institutes
• Others
By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include QIAGEN N.V., Bio-Rad Laboratories, Inc., Illumina, Inc., Labcorp Drug Development, IQVIA, Inc., Quanterix Corporation, Merck KGaA, Abbott Laboratories, Thermo Fisher Scientific Inc., and Q2 Solutions among others.
Why Purchase the Report??
• To visualize the global biomarker testing market segmentation based on test type, biomarker type, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of biomarker testing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global biomarker testing market report would provide approximately 53 tables, 47 figures and 176 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Test Type
- 3.2. Snippet by Biomarker Type
- 3.3. Snippet by Application
- 3.4. Snippet by End-User
- 3.5. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Rising research and development of new biomarker tests
- 4.1.1.2. YY
- 4.1.2. Restraints
- 4.1.2.1. High costs of test development
- 4.1.2.2. YY
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Reimbursement Analysis
- 5.6. Patent Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
- 7. By Test Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 7.1.2. Market Attractiveness Index, By Test Type
- 7.2. Tumor Testing*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Genomic Testing
- 7.4. Molecular Testing
- 7.5. Somatic Testing
- 7.6. Next Generation Sequencing
- 8. By Biomarker Type
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 8.1.2. Market Attractiveness Index, By Biomarker Type
- 8.2. Diagnostic Biomarkers*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Prognostic Biomarkers
- 8.4. Predictive Biomarkers
- 9. By Application
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
- 9.2. Drug Discovery and Development*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Disease Diagnostics
- 9.4. Disease Risk Assessment
- 9.5. Personalized Medicine
- 9.6. Others
- 10. By End-User
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
- 10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Clinical Laboratoratories
- 10.4. Academic and Research Institutes
- 10.5. Others
- 11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.3.1. U.S.
- 11.2.3.2. Canada
- 11.2.3.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.3.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.4.1. Germany
- 11.3.4.2. UK
- 11.3.4.3. France
- 11.3.4.4. Italy
- 11.3.4.5. Spain
- 11.3.4.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.4.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.4.1. Brazil
- 11.4.4.2. Argentina
- 11.4.4.3. Rest of South America
- 11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.5.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.4.1. China
- 11.5.4.2. India
- 11.5.4.3. Japan
- 11.5.4.4. Australia
- 11.5.4.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.6.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12. Competitive Landscape
- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis
- 13. Company Profiles
- 13.1. QIAGEN N.V.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. Bio-Rad Laboratories, Inc.
- 13.3. Illumina, Inc.
- 13.4. Labcorp Drug Development
- 13.5. IQVIA, Inc.
- 13.6. Quanterix Corporation
- 13.7. Merck KGaA
- 13.8. Abbott Laboratories
- 13.9. Thermo Fisher Scientific Inc.
- 13.10. Q2 Solutions
- LIST NOT EXHAUSTIVE
- 14. Appendix
- 14.1. About Us and Services
- 14.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook